Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Horizons Marijuana Life Sciences ETF (TSX: HMMJ)
6.860 CAD  -0.070 (-1.01%)
Streaming Delayed Price  /  Updated: 3:59 PM EDT, Jul 8, 2020  /  Add to My Watchlist      
View: Quote News
Fund Overview
Horizons Marijuana Life Sciences ETF
Sector
Exchange Traded TSX
Net Assets 303.33M
Inception Date
Related Funds
Quote
Price 6.860
Volume 74,165
Last Trade Jul 08, 3:59pm
Change (%)
-0.07 (-1.01%)
Prev. Close 6.930
YTD %
-19.95%
Dividend Yield 11.73%
Performance
YTD
-1.71 (-19.95%)
1 Month
-1.35 (-16.44%)
3 Month
+1.07 (18.48%)
6 Month
-1.28 (-15.72%)
1 Year
-11.00 (-61.59%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Study: 76% Of US Cannabis Consumers Want Criminal Justice Reform
A majority of cannabis consumers support cannabis criminal justice reform. That's according to exclusive information Oasis ... Read More
from Benzinga
Cannabis Experts Say Elon Musk's Outspoken Support Is Helpful, But Additional Action Is Needed
Can a prominent person create change with a statement alone? To an extent, it appears so, though experts say more is required to move ... Read More
from Benzinga
Top News
More News
1 Pot Stock That's a Hotter Buy Than Aurora and Canopy Growth
Curaleaf has more potential growth and its numbers are more impressive. Read More
from Motley Fool
Why It May Be Time to Sell Charlotte's Web
The company's coming off another lackluster quarter that showed no growth. Read More
from Motley Fool
Why Aurora's Expansion Into the U.S. Market Really Isn't All That Exciting
Investors are more bullish than they should be. Read More
from Motley Fool
4 Reasons Why Canopy Growth Could Bounce Back in 2020
The pot stock's been struggling over the past year, but there are plenty of reasons to be optimistic about its future. Read More
from Motley Fool
Tilray's CEO Expects at Least a Dozen Cannabis Bankruptcies in 2020 -- Is He Right?
COVID-19 could be what seals the fates of many pot stocks this year. Read More
from Motley Fool
Is Aurora Cannabis a Buy After Its Q3 Results?
The company's revenue was an improvement from the previous quarter, but Aurora still posted a loss. Read More
from Motley Fool
Why Is Everyone Talking About Aurora Cannabis?
Is the pot company ready to stage a comeback? Read More
from Motley Fool
Why Cannabis Investors Shouldn't Get Too Excited About the Latest Stimulus Bill
We've been here before. Read More
from Motley Fool
This Underrated Pot Stock Is a Scorching Buy
Although it's been fairly consistent, Aphria hasn't gotten much love from investors. Read More
from Motley Fool
Here's Why Cronos Still Isn't a Buy, Despite Posting a Profit and Boasting $1 Billion in Cash
The company's quarterly results are more than a little misleading. Read More
from Motley Fool
1 Marijuana Stock to Avoid at All Costs
This stock's just too risky a buy. Read More
from Motley Fool
Better Marijuana Stock to Buy: Cresco Labs or Trulieve?
Which is the safer investment to make today? Read More
from Motley Fool
The Benzinga Cannabis Capital Conference Goes Virtual: Isiah Thomas, Al Harrington And Kim Rivers Among Big Names
One of the best cannabis events in the world, the Benzinga Cannabis Capital Conference, is going virtual for its seventh ... Read More
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.